Noveris Health SciencesMYCOF 23 Days Payable is 0.00 as of Mar. 2026. GuruFocus rates MYCOF with a GF Score™ of 23/100 and a GF Value™ of $0.52 (Significantly Overvalued). Among 922 Drug Manufacturers companies, Noveris Health Sciences ranks worse than 108459.76% on this metric.
The historical rank and industry rank for Noveris Health Sciences's Days Payable or its related term are showing as below:
During the past 13 years, Noveris Health Sciences's highest Days Payable was 205.73. The lowest was 205.73. And the median was 205.73.
MYCOF's Days Payable is not ranked *
in the Drug Manufacturers industry.
Industry Median: 90.835 * Ranked among companies with meaningful Days Payable only.
Noveris Health Sciences's Days Payable
stayed the same
from Mar. 2025 (0.00) to Mar. 2026 (0.00).
stayed the same
Noveris Health Sciences Days Payable Related Terms
Noveris Health Sciences Days Payable Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Noveris Health Sciences's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Noveris Health Sciences Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Noveris Health Sciences's Days Payable distribution charts can be found below:
* The bar in red indicates where Noveris Health Sciences's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Noveris Health Sciences's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Noveris Health Sciences (MYCOF) has a Days Payable of 0.00 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Noveris Health Sciences and its competitors. Over the past decade, Noveris Health Sciences' Days Payable has ranged from 205.73 to 205.73. According to the industry distribution chart, Noveris Health Sciences ranks #999999 out of 922 companies in the Drug Manufacturers industry.
Is Noveris Health Sciences' Days Payable too high?
Noveris Health Sciences' current Days Payable is 0.00. Over the past 10 years, this metric has ranged from a low of 205.73 to a high of 205.73. Based on the distribution chart, Noveris Health Sciences ranks #999999 out of 922 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Noveris Health Sciences has a GF Score™ of 23/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Noveris Health Sciences' Days Payable compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Noveris Health Sciences ranks #999999 out of 922 companies for Days Payable. This places Noveris Health Sciences in the lower half of its industry. The industry median Days Payable is 90.84. Historically, Noveris Health Sciences' own Days Payable has ranged from 205.73 to 205.73 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.84, based on 922 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Noveris Health Sciences and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Noveris Health Sciences's current Days Payable is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Noveris Health Sciences stock overvalued right now?
Based on GuruFocus' analysis, Noveris Health Sciences (MYCOF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.52, compared to a current price of $2.00 — trading 284.6% above its estimated fair value. The current Days Payable is 0.00. Noveris Health Sciences' overall GF Score™ is 23/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Noveris Health Sciences (MYCOF), the current Days Payable is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Noveris Health Sciences (MYCOF) Overvalued in 2026?
Based on GuruFocus' analysis, Noveris Health Sciences stock appears to be overvalued.
The current stock price of $2.00 is trading 284.6% above its estimated GF Value™ of $0.52.
GuruFocus considers Noveris Health Sciences to be Significantly Overvalued.
Key valuation signals for MYCOF:
Days Payable: 0.00
GF Value™: $0.52 vs. price of $2.00 (284.6% above fair value)
No single metric tells the full story. See the MYCOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Noveris Health Sciences Inc is a biotech and life sciences company dedicated to developing and commercializing solutions for treating mental health problems and enhancing vitality. The company has a portfolio of patents it is seeking to commercialize, and is exploring opportunities in the stem cell industry. It is developing the next generation of medications and therapies to address mental health disorders such as nicotine addiction and post-traumatic stress disorder (PTSD).
23GF Score
Get the complete analysis for MYCOF
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MYCOF has been successfully added to your 
